Tag: TIDES
Aurigene’s Dr Kesavan Balakumaran shares insights on scalable peptide manufacturing at...
The presentation highlighted the importance of selecting the right development approach based on project requirements, timelines, and scale
Takeda’s dengue vaccine candidate shows positive results during 4.5 years long...
TAK-003 was generally well tolerated, and there were no important safety risks identified. No evidence of disease enhancement was observed over the 54-month follow-up exploratory analysis